IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
©2023 American Association for Cancer Research..
PURPOSE: Patients with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However, therapeutic resistance eventually emerges, often via secondary EGFR mutations or EGFR-independent mechanisms such as epithelial-to-mesenchymal transition. Treatment options after EGFR-TKI resistance are limited as anti-PD-1/PD-L1 inhibitors typically display minimal benefit. Given that IL6 is associated with worse outcomes in patients with NSCLC, we investigate whether IL6 in part contributes to this immunosuppressed phenotype.
EXPERIMENTAL DESIGN: We utilized a syngeneic genetically engineered mouse model (GEMM) of EGFR-mutant NSCLC to investigate the effects of IL6 on the tumor microenvironment and the combined efficacy of IL6 inhibition and anti-PD-1 therapy. Corresponding in vitro studies used EGFR-mutant human cell lines and clinical specimens.
RESULTS: We identified that EGFR-mutant tumors which have oncogene-independent acquired resistance to EGFR-TKIs were more mesenchymal and had markedly enhanced IL6 secretion. In EGFR-mutant GEMMs, IL6 depletion enhanced activation of infiltrating natural killer (NK)- and T-cell subpopulations and decreased immunosuppressive regulatory T and Th17 cell populations. Inhibition of IL6 increased NK- and T cell-mediated killing of human osimertinib-resistant EGFR-mutant NSCLC tumor cells in cell culture. IL6 blockade sensitized EGFR-mutant GEMM tumors to PD-1 inhibitors through an increase in tumor-infiltrating IFNγ+ CD8+ T cells.
CONCLUSIONS: These data indicate that IL6 is upregulated in EGFR-mutant NSCLC tumors with acquired EGFR-TKI resistance and suppressed T- and NK-cell function. IL6 blockade enhanced antitumor immunity and efficacy of anti-PD-1 therapy warranting future clinical combinatorial investigations.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
---|---|
Enthalten in: |
Clinical cancer research : an official journal of the American Association for Cancer Research - 29(2023), 7 vom: 03. Apr., Seite 1292-1304 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Patel, Sonia A [VerfasserIn] |
---|
Links: |
---|
Themen: |
EC 2.7.10.1 |
---|
Anmerkungen: |
Date Completed 07.04.2023 Date Revised 04.10.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1158/1078-0432.CCR-22-3379 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM351068120 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM351068120 | ||
003 | DE-627 | ||
005 | 20231226050438.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1158/1078-0432.CCR-22-3379 |2 doi | |
028 | 5 | 2 | |a pubmed24n1170.xml |
035 | |a (DE-627)NLM351068120 | ||
035 | |a (NLM)36595561 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Patel, Sonia A |e verfasserin |4 aut | |
245 | 1 | 0 | |a IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.04.2023 | ||
500 | |a Date Revised 04.10.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a ©2023 American Association for Cancer Research. | ||
520 | |a PURPOSE: Patients with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However, therapeutic resistance eventually emerges, often via secondary EGFR mutations or EGFR-independent mechanisms such as epithelial-to-mesenchymal transition. Treatment options after EGFR-TKI resistance are limited as anti-PD-1/PD-L1 inhibitors typically display minimal benefit. Given that IL6 is associated with worse outcomes in patients with NSCLC, we investigate whether IL6 in part contributes to this immunosuppressed phenotype | ||
520 | |a EXPERIMENTAL DESIGN: We utilized a syngeneic genetically engineered mouse model (GEMM) of EGFR-mutant NSCLC to investigate the effects of IL6 on the tumor microenvironment and the combined efficacy of IL6 inhibition and anti-PD-1 therapy. Corresponding in vitro studies used EGFR-mutant human cell lines and clinical specimens | ||
520 | |a RESULTS: We identified that EGFR-mutant tumors which have oncogene-independent acquired resistance to EGFR-TKIs were more mesenchymal and had markedly enhanced IL6 secretion. In EGFR-mutant GEMMs, IL6 depletion enhanced activation of infiltrating natural killer (NK)- and T-cell subpopulations and decreased immunosuppressive regulatory T and Th17 cell populations. Inhibition of IL6 increased NK- and T cell-mediated killing of human osimertinib-resistant EGFR-mutant NSCLC tumor cells in cell culture. IL6 blockade sensitized EGFR-mutant GEMM tumors to PD-1 inhibitors through an increase in tumor-infiltrating IFNγ+ CD8+ T cells | ||
520 | |a CONCLUSIONS: These data indicate that IL6 is upregulated in EGFR-mutant NSCLC tumors with acquired EGFR-TKI resistance and suppressed T- and NK-cell function. IL6 blockade enhanced antitumor immunity and efficacy of anti-PD-1 therapy warranting future clinical combinatorial investigations | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a EGFR protein, human |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a ErbB Receptors |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a Interleukin-6 |2 NLM | |
650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
700 | 1 | |a Nilsson, Monique B |e verfasserin |4 aut | |
700 | 1 | |a Yang, Yan |e verfasserin |4 aut | |
700 | 1 | |a Le, Xiuning |e verfasserin |4 aut | |
700 | 1 | |a Tran, Hai T |e verfasserin |4 aut | |
700 | 1 | |a Elamin, Yasir Y |e verfasserin |4 aut | |
700 | 1 | |a Yu, Xiaoxing |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Fahao |e verfasserin |4 aut | |
700 | 1 | |a Poteete, Alissa |e verfasserin |4 aut | |
700 | 1 | |a Ren, Xiaoyang |e verfasserin |4 aut | |
700 | 1 | |a Shen, Li |e verfasserin |4 aut | |
700 | 1 | |a Wang, Jing |e verfasserin |4 aut | |
700 | 1 | |a Moghaddam, Seyed Javad |e verfasserin |4 aut | |
700 | 1 | |a Cascone, Tina |e verfasserin |4 aut | |
700 | 1 | |a Curran, Michael |e verfasserin |4 aut | |
700 | 1 | |a Gibbons, Don L |e verfasserin |4 aut | |
700 | 1 | |a Heymach, John V |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical cancer research : an official journal of the American Association for Cancer Research |d 1995 |g 29(2023), 7 vom: 03. Apr., Seite 1292-1304 |w (DE-627)NLM09444479X |x 1557-3265 |7 nnns |
773 | 1 | 8 | |g volume:29 |g year:2023 |g number:7 |g day:03 |g month:04 |g pages:1292-1304 |
856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-22-3379 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 29 |j 2023 |e 7 |b 03 |c 04 |h 1292-1304 |